The transient receptor potential ankyrin 1 (TRPA1) channels may play a role in this multifaceted scenario, as suggested by evidence provided by our group and other researchers [16,17,18,19] showing that TRPA1 antagonism is indeed effective for abolishing migraine-like changes in preclinical models. This evidence concerns the gene TRPA1 and migraine disorder.